Amarin Corp Plc (AMRN)

[couldbebetter]

My take is that all of these injectable or infusion based AD drugs
have some very serious side effects and are a mistake for the FDA
to approve. What AMRN needs is a BP to acquire it in order to reformulate
it in a way that gives it patent protection, in order to pursue new indications
such as cancer & AD. Hoping that Denner is working to insure such a scenario
plays out. I wonder why there have been no retrospective studies on AD given
that the drug should have been used long enough by enough people for such
determinations. (My own opinion is that an honest study of Vascepa & AD would
show effectiveness as would one for Vascepa use and cancer.)